Dofequidar

• CAT Number: I001137
• CAS Number: 129716-58-1
• Molecular Formula: C30H31N3O3
• Molecular Weight: 481.59
• Purity: ≥95%
• Target: P-gp
• Solubility: 10 mM in DMSO
• Storage: Store at -20℃
• IUPAC Name: 1-[4-(2-hydroxy-3-quinolin-5-yloxypropyl)piperazin-1-yl]-2,2-diphenylethanone
• InChI: InChI=1S/C30H31N3O3/c34-25(22-36-28-15-7-14-27-26(28)13-8-16-31-27)21-32-17-19-33(20-18-32)30(35)29(23-9-3-1-4-10-23)24-11-5-2-6-12-24/h1-16,25,29,34H,17-22H2
• InChIKey: KLWUUPVJTLHYIM-UHFFFAOYSA-N
• SMILES: C1CN(CCN1CC(COC2=CC=CC3=C2C=CC=N3)O)C(=O)C(C4=CC=CC=C4)C5=CC=CC=C5

Dofequidar (Cat.No:I001137) is a selective inhibitor of P-glycoprotein (P-gp), a drug efflux pump involved in multidrug resistance. It has shown potential in overcoming drug resistance in cancer cells, enhancing the effectiveness of chemotherapy. Further research is underway to explore its clinical applications and safety profiles. 

Reference

[1]. Naito M, et al. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models. Clin Cancer Res. 2002 Feb;8(2):582-8.
[2]. Nokihara H, et al. A new quinoline derivative MS-209 reverses multidrug resistance and inhibits multiorgan metastases by P-glycoprotein-expressing human small cell lung cancer cells. Jpn J Cancer Res. 2001 Jul;92(7):785-92.
[3]. Nakanishi O, et al. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines. Oncol Res. 1997;9(2):61-9.